Ascendiant analyst Edward Woo raised the firm’s price target on RenovoRx (RNXT) to $11.50 from $11 and keeps a Buy rating on the shares. The company reported Q1 results with strong revenue growth, the analyst tells investors in a research note. The firm says the RenovoCath commercialization and positive clinical data in Q3 will be “strong catalysts” for the stock.
Confident Investing Starts Here:
- Easily unpack a company's performance with TipRanks' new KPI Data for smart investment decisions
- Receive undervalued, market resilient stocks right to your inbox with TipRanks' Smart Value Newsletter
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on RNXT:
- RenovoRx Buy Rating: Promising RenovoCath Adoption and TIGeR-PaC Study Progress Drive Positive Outlook
- RenovoRx’s Innovative Drug Delivery and Promising Clinical Trials Earn a Buy Rating
- RenovoRx Earnings Call: Positive Outlook Amid Growth
- RenovoRx Reports Promising Q1 2025 Financial Results
- RenovoRx Reports Strong Q1 2025 Financial Results
Looking for a trading platform? Check out TipRanks' Best Online Brokers , and find the ideal broker for your trades.
Report an Issue